Eisai's novel anti-epileptic perampanel moves forward in Europe
This article was originally published in Scrip
Executive Summary
Eisai's first-in-class epilepsy drug perampanel has passed its first regulatory hurdle in the EU, being accepted for review by the European Medicines Agency as an adjunctive therapy in patients with refractory partial onset seizures.